SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors scrutinize the company's heavy capital expenditures on AI and the potential cannibalization of its core seat-based licensing model. Despite strong fundamentals and record revenue growth, the community is expressing intense frustration over the stock's persistent decline, with many debating whether this represents a temporary correction or a deeper systemic repricing.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant investor interest as a high-concentration proxy for SpaceX, with market participants closely monitoring reports of an imminent IPO filing. The community is actively debating the fund's valuation relative to its NAV compared to other venture-focused investment vehicles, while anticipating that institutional demand for private unicorn exposure will drive further volatility.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as investors react to positive Phase 3 results for Zenkuda in diabetic retinopathy, which met its primary endpoint and showed significant superiority over sham treatment. The community is actively debating the stock's potential for a broader repricing and recovery, closely monitoring institutional positioning from major stakeholders like Baker Bros against the backdrop of historical volatility and high short interest.

The Shrimp Army

SHRIMPS is gaining significant attention as part of a broader, community-led trend centered on ocean-themed meme coins on the Solana network. While supporters are rallying behind its rapid price momentum and speculative potential, skeptics are cautioning investors to be wary of the volatility and risks typically associated with this sector of the crypto market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as investors focus on the company's dual-agonist VK2735 and anticipation for clinical trial catalysts, including upcoming maintenance data and the progression of Phase 3 trials. Community conversation remains heavily focused on the potential for a major partnership or acquisition, with many traders closely monitoring institutional accumulation and significant short interest as key indicators of future momentum.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is currently in the spotlight following the announcement of a strategic partnership with Mowasalat to deploy robotaxis on public roads in Doha, Qatar. Community sentiment is largely driven by this expansion into the Middle East alongside the company's aggressive efforts to scale its global autonomous vehicle fleet, leading to high call option volume and bullish momentum.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan Inc. is currently attracting significant attention following a successful earnings report that featured a revenue beat and strong guidance, driving a double-digit rally in after-hours trading. While some investors are optimistic about the company's AI-driven growth and enterprise market momentum, the community remains divided, with active discussions focused on evaluating long-term profitability against historical post-IPO volatility.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is seeing significant investor attention following the FDA approval of Optune Pax for locally advanced pancreatic cancer, the first new treatment for the condition in nearly three decades. While the community is actively debating the company's long-term commercial execution and the impact of recent Medicare billing challenges, sentiment remains divided between those betting on a potential short squeeze and those skeptical of management's ability to drive sustained revenue growth.

Designer Brands, Inc. engages in the design, production, and retail of footwear and accessory brands. It operates through the following segments: U.S. Retail, Canada Retail, Brand Portfolio, and Others. The U.S. Retail segment focuses on stores operated in the U.S. under the DSW Designer Shoe Warehouse banner and its related e-commerce site. The Canada Retail segment comprises stores operated in Canada under The Shoe Company, Shoe Warehouse, and DSW Designer Shoe Warehouse banners and related e-commerce sites. The Brand Portfolio segment includes sales from wholesale, First Cost, and direct-to-consumer e commerce sites. The Other segment refers to the ABG and Ebuys business. The company was founded on January 20, 1969 and is headquartered in Columbus, OH.

Designer Brands Inc - Ordinary Shares - Class A

Designer Brands is experiencing a volatile market reaction as traders weigh mixed earnings results against a newly announced hundred million dollar share buyback program. The community is actively debating the stock's long-term viability, balancing concerns over tightening margins and shifting consumer trends against the potential for an aggressive share reduction to drive value.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant momentum following the release of promising clinical data for its new siRNA programs targeting muscular dystrophies. Investors are actively discussing the potential for a short squeeze given the high short interest, while optimism grows around the company's platform validation and the possibility of a strategic acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ex-Div Reminder for Prospect Capital (PSEC)

Looking at the universe of stocks we cover at Dividend Channel, on 3/27/26, Prospect Capital Corporation (Symbol: PSEC) will trade ex-dividend, for its monthly dividend of $0.045, payable on 4/21/26. As a percentage of PSEC's recent stock price of $2.62, this dividend works out...

Van ECK Associates Corp Increases Holdings in Prospect Capital Corporation $PSEC

Van ECK Associates Corp boosted its position in Prospect Capital Corporation (NASDAQ:PSEC - Free Report) by 9.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with...

Prospect Capital (NASDAQ:PSEC) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Prospect Capital (NASDAQ:PSEC) Stock Price Crosses Above 200 Day Moving Average - Should You Sell...

Prospect Capital (NASDAQ:PSEC) Share Price Passes Above 200-Day Moving Average - Here's Why

Prospect Capital (NASDAQ:PSEC) Stock Passes Above 200-Day Moving Average - Here's Why...

Prospect Capital's Series A Preferred Stock Shares Cross 7.5% Yield Mark

In trading on Monday, shares of Prospect Capital Corporation's 5.35% Series A Cumulative Preferred Stock (Symbol: PSEC.PRA) were yielding above the 7.5% mark based on its quarterly dividend...

Promising Growth Stocks To Watch Now - February 22nd

Prologis, Teledyne Technologies, Ascendis Pharma A/S, Hamilton Lane, Hercules Capital, Prospect Capital, and Trinity Capital are the seven Growth stocks to watch today, according to MarketBeat's...

Looking at the universe of stocks we cover at Dividend Channel, on 2/25/26, Prospect Capital Corporation (Symbol: PSEC) will trade ex-dividend, for its monthly dividend of $0.045, payable on 3/19/26...

Growth Stocks To Follow Now - February 21st

Prospect Capital (NASDAQ:PSEC) COO Buys 942,800 Shares

Prospect Capital Corporation (NASDAQ:PSEC - Get Free Report) COO M Grier Eliasek purchased 942,800 shares of the business's stock in a transaction on Wednesday, February 11th. The shares were...

Prospect Capital (NASDAQ:PSEC) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Prospect Capital from a "buy" rating to a "hold" rating in a research report on Saturday...

Prospect Capital Corp., a traded business development company invests in middle market companies located in the United States. The fund targets companies operating across a broad range of sectors. It provides debt and equity financing for buyout, growth, development, and recapitalization. It acts as a co-investor and takes controlling interest. The company was founded on April 13, 2004 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.11	--	--	N/A
Q2 '26	$0.10	$0.19	82.34%	BEAT
Q1 '26	$0.11	$0.17	48.60%	BEAT
Q4 '25	$0.13	$0.17	34.05%	BEAT
Q3 '25	$0.14	$0.19	38.47%	BEAT

PSEC
Prospect Capital Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings

Latest PSEC News

PSECProspect Capital Corporation